Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal alimentary canal malignancies. It is the fourth most frequent cause of all cancer-related deaths in developed countries. 1 The median survival of PDAC is <6 months and the 5-year survival rate is between 3% and 5%. 
| INTRODUC TI ON
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal alimentary canal malignancies. It is the fourth most frequent cause of all cancer-related deaths in developed countries. 1 The median survival of PDAC is <6 months and the 5-year survival rate is between 3% and 5%. 2 Surgery remains the only chance of cure for PDAC. 3, 4 However, because of the vague clinical symptoms of PDAC, patients are often diagnosed late with regional invasion or distant metastasis already evident, and only 15%-25% of patients present with resectable disease at the time of primary diagnosis. 4, 5 Currently, gemcitabine, a chemotherapeutic drug, is the standard of systemic treatment for PDAC. Nevertheless, the clinical efficacy of gemcitabine is limited, 6 in addition to its high toxicity. Targeted drugs usually have low toxicity, and have shown excellent efficacy in many other cancer types. [7] [8] [9] Unfortunately, there are no targeted drugs approved for clinical use in the treatment of PDAC. Therefore, development of new potent targeted drugs is of great significance to the therapy of PDAC.
In the past decade, strenuous efforts have been undertaken on understanding the molecular and biological underpinnings of PDAC, 2, 10, 11 which revealed that mutations and/or the aberrant expression of specific protein tyrosine kinases (PTKs) were important factors responsible for the occurrence and development of PDAC. [12] [13] [14] Among these PTKs, Src is of particular importance. Activating mutations in the Src kinase are found in up to 70% of PDAC cases. 15 Moreover, aberrant Src activation is often correlated with poor clinical prognosis of PDAC patients. 15 Hence, Src inhibitors have been considered to be promising agents for the treatment of PDAC.
Currently, a number of Src inhibitors have been developed, [16] [17] [18] [19] [20] and one of them, namely dasatinib (BMS-354825), has been in phase II clinical trials for treating metastatic PDAC. 21 Unfortunately, single use of dasatinib did not show a promising therapeutic effect. 21 One of the main reasons why PDAC is difficult to treat is due to the notorious KRAS mutations, which were found in up to 90% of PDAC patients. 22, 23 Many researchers have tried to identify KRAS inhibitors and a number have indeed been discovered. 24, 25 However, the potencies of these inhibitors are not sufficient to achieve a good in vivo antitumor effect. 26, 27 Recently, Vallejo et al 28 reported that FOSL1 (also called Fra-1), which is a transcription factor, was a vulnerable oncogene in KRAS-driven pancreatic cancer, and genetic inhibition of FOSL1 was able to block the growth of KRAS-driven tumor types. Furthermore, recent studies have indicated that FOSL1 plays an important role in the regulation of epithelial-mesenchymal transition, which is associated with tumor metastasis. [29] [30] [31] [32] [33] Additionally, our data ( Figure S1 and Table S4 ) and other published data 34 all showed that pancreatic cancer tissues have a slightly higher expression of FOSL1 compared with normal pancreatic tissues. All of these results imply that agents that can downregulate the expression of FOSL1 might have potential to be used for the treatment of PDAC.
Considering the unsatisfactory antitumor efficacy of sole inhibition of the Src kinase and the pathological role of FOSL1 in KRAS-driven tumors, we hypothesized that agents that are able to inhibit the Src kinase, and concurrently downregulate the expression of FOSL1, might bring an improved clinical outcome in the treatment of PDAC. In a recent study, 35 we discovered a new drug candidate, N-(3-((4-amino-1-(4-hydroxycyclohexyl)-
(trifluoromethyl)benzamide, termed LY-1816 ( Figure 1A ). This compound showed excellent activity in inhibiting Src. In the same time, it could also significantly downregulate the expression of FOSL1. In this investigation, we evaluated the anti-PDAC activities of LY-1816 both in vitro and in vivo, and also explored the mechanisms of action of its antitumor potential.
| MATERIAL S AND ME THODS

| Compounds
LY-1816 ( Figure 1A ) was synthesized at the State Key Laboratory of Biotherapy, Sichuan University (Chengdu, China). Dasatinib and gemcitabine were acquired from commercial suppliers (Dalian Meilun Biotechnology, Liao Ning, China). Stock solutions of compounds for all in vitro assays were prepared in DMSO and then diluted in optimal medium. The final concentration of DMSO in the incubation mixture did not exceed 0.1% (v/v) in each experiment.
| Cell culture
Human pancreatic cancer cell lines were obtained from ATCC (Manassas, VA, USA). All tumor cell lines were maintained according to the ATCC guidelines for <6 months from the time they were received or thawed. No further authentication was done for tumor cell lines.
| In vitro kinase inhibition assay
The in vitro kinase enzymatic inhibition assays were carried out by the Kinase Profiling Services provided by Eurofins (Dundee, UK).
The ATP concentration used was 10 μmol/L in all assays.
| Cell proliferation assay
Cell proliferation assays were carried out as previously reported. 36 (drug diluent) added to the cells had no effect on cell proliferation.
| Colony formation assay
Cells were seeded in 6-well plates at a density of 5000-8000 cells 
| DNA synthesis assay
Cells were seeded overnight at a density of 5000-8000 cells per well in 96-well plates, and then treated with different concentrations of LY-1816 or other agents for 24 hours. Subsequently, the EdU incorporation assay was carried out on the cells according to the manufacturer's instructions (Guangzhou RiboBio, Guangdong, China).
| Apoptosis assay
The Annexin V-PI detection kit (Keygen Biotech, Jiangsu, China)
was used for apoptosis analysis. Briefly, the cells were treated with different concentrations of LY-1816 or other agents for 24 hours, then washed with PBS. Annexin V-FITC and propidium iodide (PI)
were then added according to the manufacturer's instructions, and the samples were incubated in the dark for 15 minutes. Pictures were taken by using an Olympus digital camera (Shinjuku, Tokyo, Japan) that was attached to a light microscope.
| Western blot analysis
Western blot analyses were carried out using standard methods. Ser265 , and anti-β-actin. Specific proteins were detected using the Enhanced Chemoluminescene System (Millipore).
| Wound healing assay
Wound healing assays were done following the method reported previously. 37 Cells were plated in 6-well plates at a seeding density of 
| Transwell assay
Transwell assays were carried out as described previously. 
| Subcutaneous xenograft models
All animal experiments were approved by the Animal Care and Use
Committee of Sichuan University. Six-week-old female NOD-SCID mice were purchased from HFK Bio Technology Company (Beijing, China).
Tumor xenograft models were established by s.c. injecting 100 μL tumor cell suspension (between 5 × 10 6 and 1 × 10 7 ) into the right flank of animals.
Mice were randomized into groups of 6-7 when tumors sizes reached a volume of 100-200 mm 3 . LY-1816 was dissolved in 25% (v/v) PEG400 plus 5% DMSO in deionized water. Dasatinib was suspended in a mixture of propylene glycol/water (50:50). Gemcitabine was dissolved in normal saline.
Animals were given LY-1816 (20 and 40 mg/kg), dasatinib (40 mg/kg), or vehicle once daily by oral gavage. Gemcitabine was given i.p. once a week (80 mg/kg). Tumors were measured every 3 days using calipers, and the volume was calculated using the following formula: length × width 2 × 0.5.
| Immunohistochemistry
Paraffin-embedded sections of tumors were stained with H&E using standard methods. Immunohistochemical staining was carried out using Abs from Cell Signaling Technology or Abcam (Cambridge, UK).
Staining was undertaken using frozen sections of tissue embedded at an optimal temperature. The images were captured with a Carl Zeiss digital camera (Stuttgart, Germany) attached to a light microscope. The number of Ki-67-and cleaved caspase-3-positive cells was quantified. The tumor burdens in the lungs were examined by H&E staining.
| Experimental metastasis assay
Survival data were analyzed using the Kaplan-Meier method, and statistical significance was evaluated with a log rank test by comparing the survival time of each treatment group with the control group.
| Statistical analysis
The IC 50 values were calculated with GraphPad Prism version 6.04
software. The statistical significance was determined by Student's t test and ANOVA. P < .05 was considered statistically significant.
| RE SULTS
| Enzymatic activities of LY-1816 against recombinant human protein kinases
Kinase inhibitory activities of LY-1816 against a panel of recombinant human protein kinases were measured by the "gold F I G U R E 1 Chemical structure of LY-1816 and its antiviability/proliferative activities against pancreatic ductal adenocarcinoma (PDAC) cells in vitro. A, Chemical structure of LY-1816. B, Antiviability activities of LY-1816, dasatinib, and gemcitabine against various PDAC cell lines. Every experiment was carried out in triplicate. Points, mean value; bars, SD. C, Antiproliferation activities of LY-1816 against PDAC cells by colony formation assays. Aspc-1 and Bxpc-3 cells were incubated with agents in indicated concentrations for 14 days (Aspc-1) or 18 days (Bxpc-3). Cells were stained with crystal violet and quantified. Left panels, representative images; right panels, percentages of colony numbers. Columns, mean (n = 3); bars, SD.*P < .05; **P < .01, ***P < .001, ns, not significant. D, Antiproliferation activities of LY-1816 against PDAC cells by EdU incorporation assays. Aspc-1 and Bxpc-3 cells were treated with agents in indicated concentrations for 24 hours, followed by incubation with EdU and Hoechst in sequence. The fluorescence of EdU (red) and Hoechst (blue) represent proliferating cells and cell nuclei, respectively. Scale bar = 50 mm for micrographs (left). Percentages of EdU-positive cells are presented (right). Columns, mean (n = 3); bars, SD. *P < .05; **P < .01; ***P < .001
standard" radiometric kinase assay approach (also see Zhang et al 35 ) . First, activities of LY-1816 at a single fixed concentration of 10 μmol/L were tested against a panel of 335 kinases, and the results are presented in Table S1 . Kinases that had a higher inhibition rate at 10 μmol/L were then selected for further testing for their half-maximal inhibitory concentrations (IC 50 ); the results are summarized in Table S2 . Obviously, LY-1816 is a multikinase 
| Antiviability activities of LY-1816 against PDAC cells and other cells in vitro
We (Table 1 and Figure 1B) . The inhibitory potencies of LY-1816 against these PDAC cells are superior or at least comparable to those of dasatinib or gemcitabine (Table S3) 
| Antiproliferation activities of LY-1816 against PDAC cells
We next examined the antiproliferation activity of LY-1816 in 2
representative PDAC cell lines Aspc-1 and Bxpc-3 by colony formation assays. Dasatinib and gemcitabine were also tested for 
| LY-1816 induced apoptosis of PDAC cells in vitro
Annexin V/PI staining was used to investigate the pro-apoptotic ability of LY-1816. As shown in Figure 2 , LY-1816 treatment significantly increased the annexin V and PI-positive populations in cultured Aspc-1 and Bxpc-3 cells in a dose-dependent manner, indicating a strong pro-apoptotic effect. Dasatinib and gemcitabine also could induce apoptosis in both cell lines. However, the potency was weaker than that of LY-1816. In addition, we examined the influence of LY-1816 on the MAPK and PI3K/AKT signaling pathways. Aspc-1 and Bxpc-3 cell lines were selected. As shown in Figure S2 , LY-1816 showed very weak or no impact on the phosphorylation of ERK and AKT, indicating a slight or no effect on the MAPK and PI3K/AKT signaling pathways.
| LY-1816 inhibited Src activation and FOSL1 expression in intact PDAC cells
Additionally, it has been reported that a lack of inhibition of activated STAT3 signaling could be one of the important reasons leading to the poor efficacy of dasatinib as first-line therapy in patients with metastatic PDAC. 21 We thus examined the influence of LY-1816 and dasatinib on STAT3 signaling. The results showed that dasatinib indeed showed very weak or no impact on the phosphorylation of STAT3. Interestingly, LY-1816 could significantly inhibit STAT3 phosphorylation, indicating inactivation of STAT3 signaling ( Figure S2 ).
| In vivo antitumor activity and mechanisms of action of LY-1816 in PDAC xenograft models
The in vivo antitumor activities of LY-1816 were evaluated with mouse s.c. xenograft models of Aspc-1 and Bxpc-3 (NOD-SCID mice were used). LY-1816 was given daily, orally, for 18 days at a dose of 20 or 40 mg/kg. Dasatinib (40 mg/kg/d given orally and once daily) and gemcitabine (i.v. injection at a dose of 80 mg/kg once a week) were used as positive controls. The tumor volumes were measured every 3 days.
In both Aspc-1 and Bxpc-3 models, LY-1816 showed dose-dependent tumor inhibitory activities and the 40 mg/kg dose showed a tumorinhibition rate of >90% ( Figure 4A,B) . Dasatinib and gemcitabine also showed antitumor activities in both models. However, the potencies of these 2 agents were obviously weaker than that of LY-1816. In addition, during the period of LY-1816 treatment, there was no significant decrease in body weight ( Figure 4C,D) , implying a low toxicity. 
| Antitumor metastasis ability of LY-1816 in vitro and in vivo
Wound healing assays were adopted to assess the in vitro antimetastatic effect of LY-1816. Aspc-1 and Bxpc-3 cell lines were used. ; bars, SD. *P < .05; **P < .01; ***P < .001. ns, not significant. B, Survival tests. Kaplan-Meier survival curve for every treatment group. *P < .05; **P < .01; ***P < .001. C, Representative H&E staining images of intact lung tissue taken from mice at the end of experiments. Higher magnification images of boxed regions are also shown. Scale bar = 100 mm and 50 mm for low and high magnification, respectively
As shown in Figure 6A , treatment with LY-1816 or dasatinib dosedependently reduced cell migration in both cell lines. However, gemcitabine showed very weak activity in blocking cell migration.
Transwell assays were then used to examine the ability of LY-1816 to inhibit cell invasion. The results showed that LY-1816 significantly suppressed the invasion of Aspc-1 and Bxpc-3 cells. By contrast, both dasatinib and gemcitabine showed poor ability to block cell invasion.
We further evaluated the in vivo antimetastatic effect of LY-1816 in the Miapaca-2 metastatic model. As shown in Figure 6B , the median survival time (MST) for the control group was 60 days.
In the 20 mg/kg/d LY-1861 treatment group, LY-1816 significantly prolonged the MST to 90 days, which was much longer than those of dasatinib and gemcitabine treated groups. In the 40 mg/kg/d LY-1861 treatment group, there were still 33% mice alive at day 105, when mice were killed (Table S5 ).
To understand whether there is some association between prolonged MST and reduction in lung metastases, host mice were killed at day 50 after cell injection and receiving the same treatment as above. Intact lungs from mice were examined by H&E staining. Mice treated with LY-1816 showed much more significant reduction in the size of metastatic lung nodules compared with those treated with vehicle, dasatinib, or gemcitabine ( Figure 6C ). is an important factor responsible for tumor metastasis. 33 We developed LY-1816 as a multitarget drug candidate. It potently inhibits Src and can also significantly inhibit the expression of FOSL1, even at low concentrations. In cell viability assays, LY-1816 showed excellent activity against PDAC cell lines harboring KRAS mutations (see Table   S3 ). Of note, this compound also displayed potent activity against the WT KRAS PDAC cell line Bxpc-3. A possible explanation could be that FOSL1 is also highly expressed in Bxpc-3; alternatively, LY-1816 might play its role against cell viability by strongly blocking Src, and possibly other kinases, because LY-1816 is a multikinase inhibitor. In addition, it has been reported that single use of dasatinib has shown limited efficacy in the treatment of PDAC, which was attributed to a lack of inhibition of activated STAT3 signaling. 21 LY-1816 remedies this defect of dasatinib; it is able to efficiently inhibit the phosphorylation of STAT3. Therefore, it is not surprising that LY-1816 showed more potent anti-PDAC activity than the Src inhibitor dasatinib. 
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